Growth Metrics

Kiniksa Pharmaceuticals International (KNSA) Assets (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Assets readings, the most recent being $825.3 million for Q1 2026.

  • On a quarterly basis, Assets rose 37.7% to $825.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $825.3 million, a 37.7% increase, with the full-year FY2025 number at $763.6 million, up 31.54% from a year prior.
  • Assets hit $825.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $763.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $825.3 million in Q1 2026 to a low of $210.6 million in Q2 2022.
  • Median Assets over the past 5 years was $526.3 million (2023), compared with a mean of $532.8 million.
  • Biggest five-year swings in Assets: fell 25.77% in 2022 and later soared 130.0% in 2023.
  • Kiniksa Pharmaceuticals International's Assets stood at $459.7 million in 2022, then rose by 14.5% to $526.3 million in 2023, then grew by 10.3% to $580.6 million in 2024, then skyrocketed by 31.54% to $763.6 million in 2025, then increased by 8.07% to $825.3 million in 2026.
  • The last three reported values for Assets were $825.3 million (Q1 2026), $763.6 million (Q4 2025), and $712.3 million (Q3 2025) per Business Quant data.